Abstract
BackgroundApproximately 30% of patients on dialysis received combination therapy for their phosphate binder prescription; however, few studies for combined effects of phosphate binders are reported. For the purpose of evaluating the efficacy of combination therapy, we compared the efficacy of sucroferric oxyhydroxide (PA21) combined with calcium carbonate with that of lanthanum carbonate hydrate, sevelamer hydrochloride, and ferric citrate hydrate combined with calcium carbonate.MethodsFor in vitro studies, calcium carbonate and the other phosphate binders alone or in combination were stirred in phosphate solution at pH 2–8 for 2 h. After centrifuging the suspension, the phosphorus level in the supernatant was determined. For in vivo studies, rats were orally administered calcium carbonate and the other phosphate binders (except for sevelamer hydrochloride) alone or in combination, followed by oral administration of phosphate solution adjusted to pH 2 or 7. Serum samples were collected from the rats at predetermined timepoints and the serum phosphorus levels were determined and analyzed using a two-way analysis of variance.ResultsIn the in vitro study, the measured phosphate-binding capacity of combining sevelamer hydrochloride, PA21, and lanthanum carbonate hydrate with calcium carbonate was approximately equal to or greater than the theoretical values under most conditions. Furthermore, these combined effects were insensitive to pH in that order. The measured phosphate-binding capacity of ferric citrate hydrate combined with calcium carbonate was smaller than the theoretical values, and the combination did not exhibit efficacy under any of the tested conditions. In the in vivo study, the combined effect of PA21 and calcium carbonate at both pH values and that of lanthanum carbonate hydrate and calcium carbonate at pH 2 were additive. In contrast, the combined effect of lanthanum carbonate hydrate and calcium carbonate at pH 7 and that of ferric citrate hydrate and calcium carbonate at pH 2 were antagonistic.ConclusionsThese results suggest that coadministration of PA21 and calcium carbonate showed good and relatively stable efficacy throughout the range of the gastrointestinal pH and that combining lanthanum carbonate hydrate and ferric citrate hydrate with calcium carbonate may not produce the expected efficacy under certain conditions.
Highlights
30% of patients on dialysis received combination therapy for their phosphate binder prescription; few studies for combined effects of phosphate binders are reported
For the purpose of evaluating the efficacy of combination therapy for phosphate binders, we examined the combined effect of sucroferric oxyhydroxide (PA21) and calcium carbonate in vitro and in vivo, and compared it with that of calcium carbonate in combination with other phosphate binders
For lanthanum carbonate hydrate, the binding capacity decreased with increasing pH above 5, and phosphate adsorption was hardly observed at pH 8
Summary
30% of patients on dialysis received combination therapy for their phosphate binder prescription; few studies for combined effects of phosphate binders are reported. For the purpose of evaluating the efficacy of combination therapy, we compared the efficacy of sucroferric oxyhydroxide (PA21) combined with calcium carbonate with that of lanthanum carbonate hydrate, sevelamer hydrochloride, and ferric citrate hydrate combined with calcium carbonate. Serum phosphorus level has been reported to contribute the most to mortality among values of laboratory examination (serum phosphorus, calcium, and parathyroid hormone levels) recommended to be controlled within reference values for the treatment of CKD-MBD. Restriction of dietary phosphate intake and phosphorus excretion with dialysis are performed to control serum phosphorus levels of patients on dialysis; these measures alone are not sufficient and phosphorus absorption from the gastrointestinal tract needs to be suppressed using oral phosphate binders [7]. Oral phosphate binders such as calcium carbonate, sevelamer hydrochloride, lanthanum carbonate hydrate, ferric citrate hydrate, and sucroferric oxyhydroxide are used to treat hyperphosphatemia in Japan. As a countermeasure for these issues, calcium carbonate has been used in combination with other phosphate binders
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.